Table 1.
Baseline characteristics of patients with RR-AML
| Characteristic | All patients (n=199) | IT (n=46) | NIT (n=65) | BSC (n=88) | P value |
|---|---|---|---|---|---|
| Age, mean (range), years | 63.2 (20.4-92.8) | 52.1 (20.4-74.6) | 67.7 (23-90.6) | 65.7 (21-92.8) | |
| Male, n (%) | 124 (62) | 28 (61) | 41 (63) | 55 (63) | NS |
| ELN 2010 risk classification at diagnosis, n (%)a | |||||
| Favorable | 35 (18) | 19 (41) | 6 (9) | 10 (11) | <0.001 |
| Intermediate-1 | 100 (50) | 18 (39) | 42 (65) | 40 (45) | |
| Intermediate-2 | 5 (3) | 1 (2) | 3 (5) | 1 (1) | |
| Adverse | 59 (30) | 8 (17) | 14 (22) | 37 (42) | |
| Prior hematologic malignancy, n (%) | 25 (13) | 6 (13) | 8 (12) | 11 (13) | NS |
| Lines of therapy pre-RR-AML, n (%) | |||||
| 1 | 172 (86) | 41 (89) | 57 (88) | 74 (84) | NS |
| 2 | 19 (10) | 5 (11) | 5 (8) | 9 (10) | |
| Treatment intensity pre-RR-AML, n (%) | |||||
| IT | 124 (62) | 46 (100) | 32 (49) | 46 (52) | NS |
| NIT | 75 (38) | 0 (0) | 33 (51) | 42 (48) | |
| Best response to pre-RR-AML therapy, n (%) | |||||
| CR ≥12 months | 38 (19) | 18 (39) | 11 (17) | 9 (10) | <0.001 |
| CR <12 months | 85 (43) | 22 (48) | 30 (46) | 33 (38) | |
| NCR | 76 (38) | 6 (13) | 24 (37) | 46 (52) | |
| alloSCT pre-RR-AML, n (%) | 25 (13) | 2 (4) | 8 (12) | 15 (17) | NS |
alloSCT: allogeneic stem cell transplantation; BSC: best supportive care; CR: complete response; ELN: European LeukemiaNet; IT: intensive therapy; NIT: non-intensive therapy; NCR: no complete response; NS: not significant; RR-AML: relapsed/refractory acute myeloid leukemia.
a
Rounding may cause total ≠ 100%.